Interpace Biosciences, Inc. filed a Form 8-A12B on November 5, 2026, to register its common stock, par value $0.01 per share, for listing on The Nasdaq Stock Market LLC.

Key Highlights

  • Security registered: Common Stock, par value $0.01, registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.
  • Exchange: The Nasdaq Stock Market LLC is the designated exchange for the registered securities.
  • Related S-1 filing: The description of the common stock is incorporated by reference from Exhibit 4.1 of the company's Form S-1 registration statement (File No. 333-299123), originally filed September 25, 2026.
  • Section 12(g) registration: No securities are being registered pursuant to Section 12(g) of the Exchange Act; the box for that provision was not checked.
  • Signed by: Thomas W. Burnell, Chief Executive Officer, on November 5, 2026.

Interpace Biosciences Registers Common Stock Under Section 12(b) for Nasdaq Listing

According to the filing, Interpace Biosciences, Inc., a Delaware corporation with IRS Employer Identification No. 22-2919486 and principal offices at Waterview Plaza, Suite 310, 2001 Route 46, Parsippany, NJ 07054, submitted a Form 8-A to register one class of securities under Section 12(b) of the Securities Exchange Act of 1934. The security being registered is the company's Common Stock, par value $0.01 per share, on NASDAQ:IDXG - however, the filing itself identifies the exchange only as "The Nasdaq Stock Market LLC" and does not state a ticker symbol in the registered-securities table.

The filing discloses that the description of the common stock to be registered is incorporated by reference from the section titled "Description of Registrant's Securities" in Exhibit 4.1 to the company's Form S-1 registration statement (File No. 333-299123), which was originally filed with the Securities and Exchange Commission under the Securities Act of 1933 on September 25, 2026. The company noted that no exhibits are required to be filed with this Form 8-A because no other securities of the company are registered on The Nasdaq Stock Market LLC and the securities are not being registered under Section 12(g).

The registration statement was signed on November 5, 2026, by Thomas W. Burnell in his capacity as Chief Executive Officer of Interpace Biosciences, Inc.

What Was Disclosed

Interpace Biosciences, Inc. registered its Common Stock, par value $0.01, for listing on The Nasdaq Stock Market LLC via a Form 8-A12B filed November 5, 2026, with the stock description incorporated by reference from its Form S-1 (File No. 333-299123).